Franciscus D. Suyatna
Department Of Pharmacology And Therapeutics, Faculty Of Medicine, Universitas Indonesia, Jakarta 10430

Published : 5 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 5 Documents
Search

Effect of Administration of Combination of Captopril and Celery Extract on Blood Pressure and Electrolyte Levels of Hypertensive Rats Siska Siska; Franciscus D. Suyatna; Abdul Mun'im; Anton Bahtiar
Indonesian Journal of Pharmaceutical Science and Technology Vol 7, No 3 (2020)
Publisher : Indonesian Journal of Pharmaceutical Science and Technology

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.24198/ijpst.v7i3.26732

Abstract

Based on previous reports, the combination of captopril and celery could reduce blood pressure in hypertensive patients. This study aimed to investigate the changes of blood pressure, urine volume, sodium, and potassium level, due to concomitant administration of captopril with celery extract orally in male rats induced by 4% NaCl. The blood pressure was measured using a non-invasive tail method. The urine and blood were collected, and the sodium, potassium concentration, and cumulative urine volume were measured. The combination of 5 mg/kgBW of captopril and 40 mg/kgBW of celery extract decreased the blood pressure in hypertensive rats better than 5 mg/kgBW of captopril alone. The fell in blood pressure was followed by an increase in urine volume. Urinary and serum sodium, serum potassium levels tended to increase in all treatment groups, but not significantly different from the healthy group. Urinary potassium levels tended to decrease except in the combined 5 mg/kgBW of captopril and 40 mg/kgBW of celery extract. In conclusion, oral administration of a combination of 5 mg/kgBW captopril and 40 mg/kgBW celery extract decreased the blood pressure to the standard value in NaCl-induced hypertension rats.Keywords: Apium graveolens, captopril, celery, hypertension, pharmacodynamic
Hyaluronic Acid Accelerates VEGF and PDGF Release from Advance Platelet Rich Fibrin in Diabetic Foot Ulcer Ronald Winardi Kartika; Idrus Alwi; Franciscus Dhyanagiri Suyatna; Ferry Sandra; Em Yunir; Sarwono Waspadji; Suzzana Immanuel; Todung Silalahi; Saleha Sungkar; Jusuf Rachmat; Saptawati Bardosono; Mirta Hediyati Reksodiputro
The Indonesian Biomedical Journal Vol 13, No 3 (2021)
Publisher : The Prodia Education and Research Institute (PERI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.18585/inabj.v13i3.1523

Abstract

BACKGROUND: Hyaluronic acid (HA) is an essential component of extracellular matrix and mediates signaling in wound healing. HA could induce growth factor release from Advanced Platelet Rich Fibrin (A-PRF), including Vascular Endothelial Growth Factor (VEGF) and Platelet-derived Growth Factor (PDGF). However, concentrations of the released-VEGF and PDGF have not been clearly disclosed. Therefore, current study was conducted to measure the release of these growth factors in HA + A-PRF gel of diabetic foot ulcer (DFU) subjects.METHODS: Twenty DFU subjects were included in the study and treated with A-PRF or HA+A-PRF. A-PRF was derived from autologous peripheral blood and processed with low-speed centrifugation. HA was added with a ratio of 1:0.6. A-PRF or HA + A-PRF was applied topically on DFU. Upper tips of A-PRF or HA + A-PRF gels were collected on day 0, 3 and 7 for measurements of VEGF and PDGF concentrations with Enzyme-linked Immune-sorbent Assay (ELISA) methods.RESULTS: On day-3, both VEGF and PDGF concentrations of HA + A-PRF group were significantly higher than the VEGF (p=0.000) and PDGF (p=0.019) concentrations of A-PRF group. The VEGF and PDGF concentrations were continuously and significantly increased on day-7 of HA + A-PRF group, compared to the VEGF (p=0.000) and PDGF (p=0.004) concentrations of A-PRF group.CONCLUSION: Combination HA+A-PRF induces VEGF and PDGF release from A-PRF. A mixture of A-PRF and HA could be more effective than A-PRF alone for treatment of DFU.KEYWORDS: hyaluronic acid, advanced platelet rich fibrin, PRF, growth factor, VEGF, PDGF, diabetic foot ulcer
Advance-Platelet Rich Fibrin and Hyaluronic Acid Combination Improves Interleukin-6 and Granulation Index in Diabetic Foot Ulcer Patients Ronald Winardi Kartika; Idrus Alwi; Franciscus Dhyanagiri Suyatna; Em Yunir; Sarwono Waspadji; Suzanna Immanuel; Todung Silalahi; Saleha Sungkar; Jusuf Rachmat; Saptawati Bardosono; Mirta Hediyati Reksodiputro
The Indonesian Biomedical Journal Vol 13, No 2 (2021)
Publisher : The Prodia Education and Research Institute (PERI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.18585/inabj.v13i2.1501

Abstract

BACKGROUND: Diabetic foot ulcer (DFU) is the most common and threatening complication of Diabetes Mellitus (DM). Ideal wound dressing for DFU management should relieve symptoms, provide wound protection, and encourage healing. Advanced-Platelet Rich Fibrin (A-PRF) and Hyaluronic Acid (HA) have been proven to improve wound healing process. This study was aimed to demonstrate the ability of combination of A-PRF and HA in reducing inflammation and improving DFU tissue healing.METHODS: Twenty DFU subjects were involved in this study, and divided into two groups based on the topical fibrin gel treatment: A-PRF + HA group and A-PRF only group. A-PRF was obtained by peripheral blood centrifugation. A-PRF + HA was prepared by homogening A-PRF and AH with a ratio of 1:0.6. Interleukin-6 (IL-6) level, granulation index (GI), numeric pain score (NPS), and inflammation clinical symptoms (ICS) were assessed on day-0, 3, 7 and 14.RESULTS: Wound swabs’ IL-6 level on day-7 was found to be significantly lower in A-PRF + HA compared to A-PRF alone (p=0.041). The IL-6 level reduction also found to be significant higher either in wound swabs (day 0-7, p=0.015) or fibrin gel (day 0-3, p=0.049; day 0-7, p=0.034). A-PRF + HA treatment significantly increased the GI even since day-3 (p=0.043), with lower NPS (p<0.001), and ICS score.CONCLUSION: The combination of A-PRF and HA increases the GI in DFU healing by reducing the inflammation state which will induce the angiogenesis process, as well as reducing pain in DFU subjects better than A-PRF alone.KEYWORDS: inflammation, interleukin-6, wound healing, angiogenesis, proliferation 
Model Hewan Coba pada Penelitian Diabetes Husna, Fauzul; Suyatna, Franciscus D; Arozal, Wawaimuli; Purwaningsih, Erni H
Pharmaceutical Sciences and Research Vol. 6, No. 3
Publisher : UI Scholars Hub

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

The animal model has been widely used and contributed vastly to the scientific research over the years. While it can be used as an alternate subject in a study, the selection of the animal is crucial to assess and investigate the influence of the environment and genes on the pathogenesis of a disease. Many factors contribute to the choosing of the animal. They can be ranged from the similarities with the modelled object, easily looked after with less expensive cost, good reproductive performance, ability to produce blood and tissue samples, well-known genetic composition, and the status of the disease can be explained. Research has been taking place to investigate and find the best approach to prevent and deal with diabetes mellitus (DM) and insulin resistance and its complications. It starts with an initial in vitro method and finished with a clinical trial. Similarly, a series of in vivo studies using the animal model has been done aiming at figuring out its conditions or diseases that are identical to that of humans. This article discusses a variety of animal models frequently used in DM research.
Interleukin-1 beta (IL-1β) and interleukin-6 (IL-6) as proinflammatory cytokines in traumatic brain injury (TBI) of rat (Sprague-Dawley) : A study of propofol administration Riyadh Firdaus; Franciscus Dhyana Giri Suyatna; Aida Rosita Tantri; Yetty Ramli; Ekowati Handharyani; Arni Diana Fitri
Journal of Global Pharma Technology Volume 12 Issue 11 (2020) Nov. 2020
Publisher : Journal of Global Pharma Technology

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (756.843 KB)

Abstract

The increase in the prevalence of traumatic brain injury (TBI) followed by increased morbidity and mortality challenges anesthetists to perform the treatment patients with TBI. Menwhile, interleukin-1 beta (IL-1β) and interleukin-6 (IL-6) are the first pro-inflammatory markers expressed after secondary injury occurs. In addition, propofol (2,6-disopropylphenol) is a short-acting intravenous agent that reported to play role in inflammatory process. This study aims to determine the effects of propofol administration on the neuroinflammatory pathway. Thirty adult female Sprague Dawley rats were randomly assigned as TBI rats (T), rats that received propofol infusion (P), or TBI rats that received propofol infusion (TP). The rat model of TBI was developed using the Marmarou Weight Drop method. Clinical assessment was performed using the Neurobehavioral Severity Score-Revised (NSS-R). Brain tissues were taken 24 h after TBI and the levels of interleukin-1 (IL-1) and interleukin-6 (IL-6) mRNA expression levels were examined using qRT-PCR, while the concentration were examined using ELISA and immunohistochemistry. On clinical examination, a decrease in the median value of NSS-R in the TP group was found from 30th minute to 120th minute. 24 hours after the occurrence of TBI, there was a decrease in both the TP and T groups. However, the NSS-R values in the TP group were lower than those in the T group. The expression of IL-1β was found in the nuclei and cytosol, while IL-6 was found in the axons and cytosol. The expression and concentration of IL-1β and IL-6 were the highest in the TP group, followed by the P and then the T group. Propofol can improve neurological function in rats with TBI, probably through the mechanism involves neuroinflammatory pathways, particularly IL-1β and IL-6.